TRACON Pharmaceuticals (NASDAQ:TCON) Coverage Initiated at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a note issued to investors on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Trading Down 26.0 %

TCON stock opened at $0.03 on Monday. The stock has a 50-day moving average price of $0.04 and a two-hundred day moving average price of $0.30. TRACON Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $14.75. The stock has a market cap of $109,802.00, a PE ratio of 0.01 and a beta of 1.37.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.